Payment overview · 2025
General Payments
2 reported records · 1 companies
Healthcare provider profile · identity verified
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CARTERSVILLE, GA · NPI 1932610185
Verified facts
CMS Open Payments records show Ashley Pritchett Simms, NP-C received $49.84 in general payments during 2025 across 2 reported records.
Genentech USA, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
2 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $49.84 | 100.0% | 2 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.84 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $49.84 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 181 | 60 |
| Lisinopril | Lisinopril | 116 | 49 |
| Omeprazole | Omeprazole | 116 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 35 |
| Trazodone Hcl | Trazodone Hcl | 83 | 24 |
| Metformin Hcl | Metformin Hcl | 76 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 22 |
| Gabapentin | Gabapentin | 62 | 16 |
| Losartan Potassium | Losartan Potassium | 62 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 19 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Simvastatin | Simvastatin | 56 | 17 |
| Alendronate Sodium | Alendronate Sodium | 53 | 19 |
| Meloxicam | Meloxicam | 49 | 20 |
| Metformin Hcl Er | Metformin Hcl | 48 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 15 |
| Famotidine | Famotidine | 47 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 11 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 44 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 14 |
| Mupirocin | Mupirocin | 42 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 30 |
| Furosemide | Furosemide | 40 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | 13 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 27 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | 12 |
| Tramadol Hcl | Tramadol Hcl | 23 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Atenolol | Atenolol | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 11 |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Azithromycin | Azithromycin | 15 | 14 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.84 · 2 records | Genentech USA, Inc. | Tecentriq | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error